Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Actinium Pharmaceuticals Inc ATNM

Healthcare Biotechnology
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:ATNM)

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

PR Newswire 4 days ago

Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Accesswire November 4, 2024

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

PR Newswire November 4, 2024

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud

Accesswire November 3, 2024

Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm

Accesswire November 2, 2024

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud

Accesswire October 31, 2024

Actinium Pharmaceuticals, Inc. Is Being Investigated For Violations Of Securities Laws And Affected Shareholders Should Contact The Schall Law Firm

Accesswire October 30, 2024

The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into Actinium Pharmaceuticals Inc For Fraud

Accesswire October 29, 2024

The Schall Law Firm Encourages Investors To Join An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud

Accesswire October 28, 2024
View More News ››

Opinion & Analysis (NYSEAM:ATNM)

2017 Small-Cap Biotech Watchlist update: up 21% at the end of Q2/17

The Life Sciences Report July 14, 2017

2017 Small-Cap biotech watchlist update: holding steady in a volatile market

The Life Sciences Report April 21, 2017

2017 Small-Cap Biotech Watchlist: takeaways for investors

The Life Sciences Report January 19, 2017

19 companies selected for the 2017 Small-Cap Biotech Watchlist

The Life Sciences Report January 5, 2017

Radioimmunotherapy 2.0:Actinium sets eyes on bone marrow transplant and AML with later stage programs

The Life Sciences Report August 17, 2016
View More Opinion ››

Bullboard Posts (NYSEAM:ATNM)

ATNM Price Target Alert: $5.00. Issued by Maxim Group

BREAKING NEWS: $ATNM ATNM Price Target Alert: $5.00. Issued by Maxim Group2024-08-06 09:00:09 ET Jason McCarthy from Maxim Group issued...
whytestocks - August 6, 2024

Actinium Announces Iomab-B Markedly Increases Long Term Surv

NEWS: $ATNM Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or...
whytestocks - February 26, 2024

How to Take Advantage of moves in (ATNM)

BREAKING NEWS: $ATNM How to Take Advantage of moves in (ATNM)2024-02-16 07:20:00 ET Stock Traders Daily has produced this trading report...
whytestocks - February 16, 2024

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
EllaMae - April 13, 2023

And good supporting article!

https://trendingmarketnews.com/biotechs-next-generational-breakout/
BryceCanada - November 2, 2022

Excellent YT analysis on ATNM!

https://youtu.be/EBO7c8N5bSI
BryceCanada - November 2, 2022
View more Bullboard ››

Electrum Discovery Corp.

Electrum Discovery Corp.

Electrum Discovery Corp., formerly Medgold Resources Corp., is a Canada-based mineral exploration and development company ...
View More »